Bank of America
VRTX icon

Bank of America’s Vertex Pharmaceuticals VRTX Stock Holding History

Bank of America’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-48,500
Closed -$19M – 8387
2025
Q3 		$19M Buy
48,500
+46,000
+1,840% +$19.2M ﹤0.01% 2667
2025
Q2 		$1.11M Sell
2,500
-2,900
-54% -$1.34M ﹤0.01% 5233
2025
Q1 		$2.62M Sell
5,400
-5,100
-49% -$2.38M ﹤0.01% 4433
2024
Q4 		$4.23M Buy
10,500
+100
+1% +$46.4K ﹤0.01% 3745
2024
Q3 		$4.84M Hold
10,400
– – ﹤0.01% 3762
2024
Q2 		$4.87M Sell
10,400
-86,700
-89% -$37.6M ﹤0.01% 3652
2024
Q1 		$40.6M Sell
97,100
-21,500
-18% -$9.09M ﹤0.01% 1634
2023
Q4 		$48.3M Buy
118,600
+80,000
+207% +$29.6M ﹤0.01% 1382
2023
Q3 		$13.4M Sell
38,600
-28,400
-42% -$9.93M ﹤0.01% 2426
2023
Q2 		$23.6M Buy
67,000
+7,700
+13% +$2.59M ﹤0.01% 1871
2023
Q1 		$18.7M Buy
59,300
+4,900
+9% +$1.47M ﹤0.01% 2187
2022
Q4 		$15.7M Buy
54,400
+15,800
+41% +$4.82M ﹤0.01% 2219
2022
Q3 		$11.2M Buy
+38,600
New +$11.1M ﹤0.01% 2500
2022
Q2 		– Sell
-6,700
Closed -$1.75M – 8414
2022
Q1 		$1.75M Buy
6,700
+4,500
+205% +$1.07M ﹤0.01% 4711
2021
Q4 		$483K Sell
2,200
-97,300
-98% -$18.9M ﹤0.01% 5903
2021
Q3 		$18M Buy
+99,500
New +$19.4M ﹤0.01% 2265
2021
Q2 		– Sell
-58,200
Closed -$12.5M – 8113
2021
Q1 		$12.5M Buy
+58,200
New +$12.8M ﹤0.01% 2508
2020
Q1 		– Sell
-135,100
Closed -$29.6M – 7273
2019
Q4 		$29.6M Buy
135,100
+16,800
+14% +$3.4M ﹤0.01% 1552
2019
Q3 		$20M Sell
118,300
-29,600
-20% -$5.24M ﹤0.01% 1826
2019
Q2 		$27.1M Buy
147,900
+67,200
+83% +$11.7M ﹤0.01% 1594
2019
Q1 		$14.8M Sell
80,700
-293,300
-78% -$54.2M ﹤0.01% 2113
2018
Q4 		$62M Buy
374,000
+297,000
+386% +$51.5M 0.01% 886
2018
Q3 		$14.8M Sell
77,000
-45,000
-37% -$8.01M ﹤0.01% 2093
2018
Q2 		$20.7M Buy
122,000
+60,800
+99% +$9.42M ﹤0.01% 1783
2018
Q1 		$9.97M Buy
61,200
+7,800
+15% +$1.27M ﹤0.01% 2415
2017
Q4 		$8M Buy
53,400
+28,900
+118% +$4.28M ﹤0.01% 2674
2017
Q3 		$3.73M Buy
+24,500
New +$3.69M ﹤0.01% 3446
2017
Q2 		– Sell
-51,400
Closed -$5.62M – 7190
2017
Q1 		$5.62M Buy
51,400
+18,300
+55% +$1.61M ﹤0.01% 2908
2016
Q4 		$2.44M Buy
33,100
+28,000
+549% +$2.28M ﹤0.01% 3602
2016
Q3 		$445K Buy
+5,100
New +$482K ﹤0.01% 4708
2016
Q2 		– Sell
-43,700
Closed -$3.47M – 7407
2016
Q1 		$3.47M Buy
+43,700
New +$3.95M ﹤0.01% 3094
2015
Q4 		– Sell
-2,500
Closed -$260K – 7484
2015
Q3 		$260K Buy
+2,500
New +$321K ﹤0.01% 5195
2015
Q1 		– Sell
-111,500
Closed -$13.2M – 7606
2014
Q4 		$13.2M Sell
111,500
-42,100
-27% -$4.74M ﹤0.01% 1708
2014
Q3 		$17.3M Sell
153,600
-88,000
-36% -$8.38M 0.01% 1511
2014
Q2 		$22.9M Buy
241,600
+57,400
+31% +$4.02M 0.01% 1307
2014
Q1 		$13M Sell
184,200
-27,600
-13% -$2.19M ﹤0.01% 1578
2013
Q4 		$15.7M Buy
211,800
+159,800
+307% +$11.1M 0.01% 1491
2013
Q3 		$3.94M Sell
52,000
-1,400
-3% -$111K ﹤0.01% 2610
2013
Q2 		$4.28M Buy
+53,400
New +$3.93M ﹤0.01% 2429

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bank of America's VRTX Position: Q1 2026 in Review

Bank of America reduced its Vertex Pharmaceuticals (VRTX) stake by 2% in Q1 2026, selling an estimated $27.4M and leaving 2,878,183 shares worth $1.29B. The position accounts for 0.09% of the portfolio, ranked #207.

Bank of America first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.39B in Q1 2025. 1,692 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Bank of America held 2,878,183 shares of Vertex Pharmaceuticals worth $1.29B as of Q1 2026.
  • Bank of America sold 58,847 Vertex Pharmaceuticals shares in Q1 2026, an estimated $27.4M.
  • Vertex Pharmaceuticals made up 0.09% of Bank of America's portfolio in Q1 2026, its #207 holding.
  • Bank of America first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Bank of America's Vertex Pharmaceuticals position peaked at $1.39B in Q1 2025.
  • 1,692 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.